Welcome to the ‘Thrombosis Adviser’ Knowledge Base

This section provides an overview of the epidemiology and burden of cancer-associated thrombosis, current guideline recommendations for its prevention and treatment, and ongoing research.

Venous Thrombosis

Introduction

An introduction to venous thromboembolic disorders, their incidence and prevalence, and risk factors

Deep Vein Thrombosis

Introduction and Diagnosis

An introduction to DVT and its clinical presentation and diagnosis

Pulmonary Embolism

Introduction and Diagnosis

An introduction to PE and its clinical presentation and diagnosis

Prevention

Introduction

VTE is a major healthcare burden

Anticoagulant Therapy

Anticoagulant therapy in patients with VTE

Other Options

Other options for thromboprophylaxis

Treatment

Treatment of DVT and PE

VTE in Special Populations

Patients with VTE and Renal Impairment

Patients with VTE and renal impairment are at high risk of thrombotic events

Frail and Elderly Patients with VTE

Elderly patients with frailty are at increased risk of thrombotic events. Treatment outcomes with non-vitamin K antagonist oral anticoagulants (NOACs) from clinical studies are important to consider in this subgroup.

Extended Treatment

The secondary prevention of venous thromboembolism, recurrent VTE and extended anticoagulant treatment

Complications

The complications of VTE, including PTS and CTEPH

Cancer-Associated Thrombosis

Introduction to Cancer-Associated Thrombosis

Learn about the epidemiology of cancer-associated thrombosis and its risk factors

Prevention of Cancer-Associated Thrombosis

Get up to date on current guidelines for preventing cancer-associated thrombosis in different patient groups

CAT Treatment and Prevention of Recurrent Events

Find out how different anticoagulant regimens are used for the treatment of cancer-associated thrombosis and prevention of recurrent events